Mirati Therapeutics (NASDAQ:MRTX – Free Report) had its target price lifted by Oppenheimer from $56.00 to $62.00 in a research report released on Wednesday morning, MarketBeat reports. They currently have an outperform rating on the biotechnology company’s stock. MRTX has been the subject of a number of other reports. BMO Capital Markets decreased their price […]
Mirati Therapeutics (NASDAQ:MRTX – Free Report) had its price objective upped by Oppenheimer from $56.00 to $62.00 in a research note published on Wednesday, MarketBeat reports. They currently have an outperform rating on the biotechnology company’s stock. Other analysts have also issued research reports about the company. Scotiabank began coverage on Mirati Therapeutics in a […]
B Riley Weighs in on Mirati Therapeutics, Inc s Q3 2023 Earnings (NASDAQ:MRTX) wkrb13.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wkrb13.com Daily Mail and Mail on Sunday newspapers.
Mirati Therapeutics (NASDAQ:MRTX) Stock Rating Upgraded by B Riley modernreaders.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from modernreaders.com Daily Mail and Mail on Sunday newspapers.
Mirati Therapeutics (NASDAQ:MRTX – Get Free Report) announced its quarterly earnings results on Tuesday. The biotechnology company reported ($3.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.23) by $0.19, Briefing.com reports. Mirati Therapeutics had a negative net margin of 3,901.06% and a negative return on equity of 71.90%. The company […]